Khosla S, Patel V M, Hay I D, Schaid D J, Grant C S, van Heerden J A, Thibodeau S N
Department of Endocrinology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
J Clin Invest. 1991 May;87(5):1691-9. doi: 10.1172/JCI115186.
Loss of heterozygosity (LOH) at specific loci may help localize tumor suppressor genes involved in the formation of various familial and sporadic tumors. In addition, the genetic loci for a number of familial tumor syndromes have been mapped by linkage analysis. To explore the possible role of tumor suppressor genes in endocrine tumors, we tested 41 pheochromocytomas (34 sporadic and 7 familial) and 11 medullary thyroid cancers (MTC) (10 sporadic and 1 familial) for LOH near a variety of potentially important genetic loci: (a) the multiple endocrine neoplasia type 2A (MEN 2A) locus on chromosome 10; (b) the von Hippel-Lindau locus on 3p; and (c) the p53 and neurofibromatosis 1 loci on 17. We also examined chromosomes 1p and 22q because previous studies in a small number of pheochromocytomas and MTCs suggested LOH in these regions. Background rates for LOH were assessed using several "random" probes. Finally, we examined a number of clinical and histologic characteristics of these tumors for possible correlations with specific genetic alterations. LOH in the region of the MEN 2A locus was uncommon (0% for MTCs, 5% for pheochromocytomas). However, we found significant allelic losses in pheochromocytomas on chromosomes 1p (42%), 3p (16%), 17p (24%), and 22q (31%). We also noted a correlation between LOH on 1p and urinary excretion of metanephrine by these patients (P = 0.02). LOH on 1p, 3p, and 17p also appeared to be associated with increased tumor volume. Analysis of the smaller number of MTCs demonstrated allelic losses on chromosomes 1p and 22q. Our results suggest that tumor formation and/or progression in pheochromocytomas and MTCs involves multiple genes, analogous with the model proposed for colon carcinoma.
特定基因座杂合性缺失(LOH)可能有助于定位参与各种家族性和散发性肿瘤形成的肿瘤抑制基因。此外,通过连锁分析已绘制出许多家族性肿瘤综合征的基因座。为了探究肿瘤抑制基因在内分泌肿瘤中的可能作用,我们检测了41例嗜铬细胞瘤(34例散发性和7例家族性)和11例甲状腺髓样癌(MTC)(10例散发性和1例家族性),以检测多种潜在重要基因座附近的LOH:(a)10号染色体上的2A型多发性内分泌腺瘤(MEN 2A)基因座;(b)3p上的von Hippel-Lindau基因座;以及(c)17号染色体上的p53和神经纤维瘤病1基因座。我们还检查了1p和22q染色体,因为先前对少数嗜铬细胞瘤和MTC的研究表明这些区域存在LOH。使用几种“随机”探针评估LOH的背景率。最后,我们检查了这些肿瘤的一些临床和组织学特征,以寻找与特定基因改变的可能相关性。MEN 2A基因座区域的LOH并不常见(MTC为0%,嗜铬细胞瘤为5%)。然而,我们发现嗜铬细胞瘤在1p(42%)、3p(16%)、17p(24%)和22q(31%)染色体上存在显著的等位基因缺失。我们还注意到这些患者1p上的LOH与间甲肾上腺素的尿排泄之间存在相关性(P = 0.02)。1p、3p和17p上的LOH似乎也与肿瘤体积增加有关。对数量较少的MTC的分析显示1p和22q染色体上等位基因缺失。我们的结果表明,嗜铬细胞瘤和MTC中的肿瘤形成和/或进展涉及多个基因,这与结肠癌提出的模型类似。